WCBA
VRTX icon

Weaver C. Barksdale & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-74
Closed -$6K – 567
2013
Q2 		$6K Buy
+74
New +$5.45K 0.01% 351

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Weaver C. Barksdale & Associates's VRTX Position: Q3 2013 in Review

Weaver C. Barksdale & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q3 2013, closing a stake of 74 shares — an estimated $6K sold.

Weaver C. Barksdale & Associates first reported a position in VRTX in Q2 2013 and held it in 1 quarter. The position peaked at $6K in Q2 2013. 403 funds tracked by Wall St. Rank hold VRTX as of Q3 2013.

  • Weaver C. Barksdale & Associates reported no remaining Vertex Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 74 Vertex Pharmaceuticals shares in Q3 2013, an estimated $6K.
  • Weaver C. Barksdale & Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Weaver C. Barksdale & Associates's Vertex Pharmaceuticals position peaked at $6K in Q2 2013.
  • 403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2013.

Based on Weaver C. Barksdale & Associates's 13F filing for Q3 2013, filed 24 Oct 2013.